INNT Insider Trading Activity and SEC Form 4 Filings
INNT insider trading summary
No open-market insider purchases or sales of Innovate Biopharmaceuticals, Inc. (INNT) have been reported on SEC Form 4 in the past 12 months.
Latest INNT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 28, 2019 | Sandeep Laumas | CEO, Executive Chairman | Buy | $5K (4,000 @ $1.15) |
| Jun 13, 2019 | Sandeep Laumas | CEO, Executive Chairman | Buy | $495 (409 @ $1.21) |
| Jun 13, 2019 | Sandeep Laumas | CEO, Executive Chairman | Buy | $721 (591 @ $1.22) |
| May 30, 2019 | Jay P. Madan | President | Buy | $7K (5,000 @ $1.32) |
| May 24, 2019 | Roy Proujansky | Director | Buy | $1K (1,000 @ $1.28) |
| May 22, 2019 | Sandeep Laumas | CEO, Executive Chairman | Buy | $7K (5,000 @ $1.38) |
| Nov 30, 2018 | Sandeep Laumas | Executive Chairman | Buy | $3K (1,000 @ $2.62) |
| Nov 30, 2018 | Sandeep Laumas | Executive Chairman | Buy | $3K (1,000 @ $2.64) |
| Nov 30, 2018 | Roy Proujansky | Director | Buy | $4K (1,400 @ $2.63) |
| Nov 30, 2018 | Sandeep Laumas | Executive Chairman | Buy | $3K (1,000 @ $2.63) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.